A Phase I/II Dose-Escalation Trial of Bevacizumab in Previously Treated Metastatic Breast Cancer

Melody A. Cobleigh, Virginia K. Langmuir, George W. Sledge, Kathy Miller, Latrice Haney, William F. Novotny, James D. Reimann, Amy Vassel

Research output: Contribution to journalArticle

423 Citations (Scopus)

Abstract

Vascular endothelial growth factor promotes angiogenesis, an important mediator of growth and metastasis in human breast cancer. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor, is under investigation as an anti-angiogenic agent. This phase I/II trial evaluated the safety and efficacy of bevacizumab in patients with previously treated metastatic breast cancer. Seventy-five patients were treated with escalating doses of bevacizumab ranging from 3 mg/kg to 20 mg/kg administered intravenously every other week. Tumor response was assessed before the sixth (70 days) and 12th (154 days) doses. Safety was evaluated during every cycle. Eighteen patients were treated at 3 mg/kg, 41 at 10 mg/kg, and 16 at 20 mg/kg. Four patients discontinued study treatment because of an adverse event. Hypertension was reported as an adverse event in 17 patients (22%). The overall response rate was 9.3% (confirmed response rate, 6.7%). The median duration of confirmed response was 5.5 months (range, 2.3 to 13.7 months). At the final tumor assessment on day 154, 12 of 75 patients (16%) had stable disease or an ongoing response. The optimal dose of bevacizumab in this trial was 10 mg/kg every other week and toxicity was acceptable. These data support the initiation of trials in metastatic breast cancer combining bevacizumab with chemotherapy.

Original languageEnglish (US)
Pages (from-to)117-124
Number of pages8
JournalSeminars in Oncology
Volume30
Issue number5 SUPPL. 16
StatePublished - Oct 2003
Externally publishedYes

Fingerprint

Breast Neoplasms
Vascular Endothelial Growth Factor A
Safety
Bevacizumab
Neoplasms
Monoclonal Antibodies
Neoplasm Metastasis
Hypertension
Drug Therapy
Growth
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Cobleigh, M. A., Langmuir, V. K., Sledge, G. W., Miller, K., Haney, L., Novotny, W. F., ... Vassel, A. (2003). A Phase I/II Dose-Escalation Trial of Bevacizumab in Previously Treated Metastatic Breast Cancer. Seminars in Oncology, 30(5 SUPPL. 16), 117-124.

A Phase I/II Dose-Escalation Trial of Bevacizumab in Previously Treated Metastatic Breast Cancer. / Cobleigh, Melody A.; Langmuir, Virginia K.; Sledge, George W.; Miller, Kathy; Haney, Latrice; Novotny, William F.; Reimann, James D.; Vassel, Amy.

In: Seminars in Oncology, Vol. 30, No. 5 SUPPL. 16, 10.2003, p. 117-124.

Research output: Contribution to journalArticle

Cobleigh, MA, Langmuir, VK, Sledge, GW, Miller, K, Haney, L, Novotny, WF, Reimann, JD & Vassel, A 2003, 'A Phase I/II Dose-Escalation Trial of Bevacizumab in Previously Treated Metastatic Breast Cancer', Seminars in Oncology, vol. 30, no. 5 SUPPL. 16, pp. 117-124.
Cobleigh MA, Langmuir VK, Sledge GW, Miller K, Haney L, Novotny WF et al. A Phase I/II Dose-Escalation Trial of Bevacizumab in Previously Treated Metastatic Breast Cancer. Seminars in Oncology. 2003 Oct;30(5 SUPPL. 16):117-124.
Cobleigh, Melody A. ; Langmuir, Virginia K. ; Sledge, George W. ; Miller, Kathy ; Haney, Latrice ; Novotny, William F. ; Reimann, James D. ; Vassel, Amy. / A Phase I/II Dose-Escalation Trial of Bevacizumab in Previously Treated Metastatic Breast Cancer. In: Seminars in Oncology. 2003 ; Vol. 30, No. 5 SUPPL. 16. pp. 117-124.
@article{bb222a7710da41f4982741bdc51c6e1e,
title = "A Phase I/II Dose-Escalation Trial of Bevacizumab in Previously Treated Metastatic Breast Cancer",
abstract = "Vascular endothelial growth factor promotes angiogenesis, an important mediator of growth and metastasis in human breast cancer. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor, is under investigation as an anti-angiogenic agent. This phase I/II trial evaluated the safety and efficacy of bevacizumab in patients with previously treated metastatic breast cancer. Seventy-five patients were treated with escalating doses of bevacizumab ranging from 3 mg/kg to 20 mg/kg administered intravenously every other week. Tumor response was assessed before the sixth (70 days) and 12th (154 days) doses. Safety was evaluated during every cycle. Eighteen patients were treated at 3 mg/kg, 41 at 10 mg/kg, and 16 at 20 mg/kg. Four patients discontinued study treatment because of an adverse event. Hypertension was reported as an adverse event in 17 patients (22{\%}). The overall response rate was 9.3{\%} (confirmed response rate, 6.7{\%}). The median duration of confirmed response was 5.5 months (range, 2.3 to 13.7 months). At the final tumor assessment on day 154, 12 of 75 patients (16{\%}) had stable disease or an ongoing response. The optimal dose of bevacizumab in this trial was 10 mg/kg every other week and toxicity was acceptable. These data support the initiation of trials in metastatic breast cancer combining bevacizumab with chemotherapy.",
author = "Cobleigh, {Melody A.} and Langmuir, {Virginia K.} and Sledge, {George W.} and Kathy Miller and Latrice Haney and Novotny, {William F.} and Reimann, {James D.} and Amy Vassel",
year = "2003",
month = "10",
language = "English (US)",
volume = "30",
pages = "117--124",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "5 SUPPL. 16",

}

TY - JOUR

T1 - A Phase I/II Dose-Escalation Trial of Bevacizumab in Previously Treated Metastatic Breast Cancer

AU - Cobleigh, Melody A.

AU - Langmuir, Virginia K.

AU - Sledge, George W.

AU - Miller, Kathy

AU - Haney, Latrice

AU - Novotny, William F.

AU - Reimann, James D.

AU - Vassel, Amy

PY - 2003/10

Y1 - 2003/10

N2 - Vascular endothelial growth factor promotes angiogenesis, an important mediator of growth and metastasis in human breast cancer. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor, is under investigation as an anti-angiogenic agent. This phase I/II trial evaluated the safety and efficacy of bevacizumab in patients with previously treated metastatic breast cancer. Seventy-five patients were treated with escalating doses of bevacizumab ranging from 3 mg/kg to 20 mg/kg administered intravenously every other week. Tumor response was assessed before the sixth (70 days) and 12th (154 days) doses. Safety was evaluated during every cycle. Eighteen patients were treated at 3 mg/kg, 41 at 10 mg/kg, and 16 at 20 mg/kg. Four patients discontinued study treatment because of an adverse event. Hypertension was reported as an adverse event in 17 patients (22%). The overall response rate was 9.3% (confirmed response rate, 6.7%). The median duration of confirmed response was 5.5 months (range, 2.3 to 13.7 months). At the final tumor assessment on day 154, 12 of 75 patients (16%) had stable disease or an ongoing response. The optimal dose of bevacizumab in this trial was 10 mg/kg every other week and toxicity was acceptable. These data support the initiation of trials in metastatic breast cancer combining bevacizumab with chemotherapy.

AB - Vascular endothelial growth factor promotes angiogenesis, an important mediator of growth and metastasis in human breast cancer. Bevacizumab, a monoclonal antibody to vascular endothelial growth factor, is under investigation as an anti-angiogenic agent. This phase I/II trial evaluated the safety and efficacy of bevacizumab in patients with previously treated metastatic breast cancer. Seventy-five patients were treated with escalating doses of bevacizumab ranging from 3 mg/kg to 20 mg/kg administered intravenously every other week. Tumor response was assessed before the sixth (70 days) and 12th (154 days) doses. Safety was evaluated during every cycle. Eighteen patients were treated at 3 mg/kg, 41 at 10 mg/kg, and 16 at 20 mg/kg. Four patients discontinued study treatment because of an adverse event. Hypertension was reported as an adverse event in 17 patients (22%). The overall response rate was 9.3% (confirmed response rate, 6.7%). The median duration of confirmed response was 5.5 months (range, 2.3 to 13.7 months). At the final tumor assessment on day 154, 12 of 75 patients (16%) had stable disease or an ongoing response. The optimal dose of bevacizumab in this trial was 10 mg/kg every other week and toxicity was acceptable. These data support the initiation of trials in metastatic breast cancer combining bevacizumab with chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0242468884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242468884&partnerID=8YFLogxK

M3 - Article

C2 - 14613032

AN - SCOPUS:0242468884

VL - 30

SP - 117

EP - 124

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 5 SUPPL. 16

ER -